KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$32.7 billion.

  • Gsk's Total Non-Current Liabilities fell 883.69% to -$32.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 billion, marking a year-over-year decrease of 883.69%. This contributed to the annual value of -$31.5 billion for FY2024, which is 20088.14% down from last year.
  • Per Gsk's latest filing, its Total Non-Current Liabilities stood at -$32.7 billion for Q3 2025, which was down 883.69% from -$32.7 billion recorded in Q2 2025.
  • Gsk's Total Non-Current Liabilities' 5-year high stood at $46.0 billion during Q4 2021, with a 5-year trough of -$50.7 billion in Q1 2021.
  • For the 5-year period, Gsk's Total Non-Current Liabilities averaged around -$23.5 billion, with its median value being -$32.3 billion (2023).
  • Per our database at Business Quant, Gsk's Total Non-Current Liabilities skyrocketed by 6522.7% in 2022 and then plummeted by 20151.19% in 2024.
  • Quarter analysis of 5 years shows Gsk's Total Non-Current Liabilities stood at $46.0 billion in 2021, then crashed by 30.47% to $32.0 billion in 2022, then fell by 2.33% to $31.2 billion in 2023, then plummeted by 201.51% to -$31.7 billion in 2024, then decreased by 3.29% to -$32.7 billion in 2025.
  • Its last three reported values are -$32.7 billion in Q3 2025, -$32.7 billion for Q2 2025, and -$33.0 billion during Q1 2025.